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ABSTRACT: Studies from the UK and USA suggest that frequent use of paracetamol
(acetaminophen) may increase the risk of asthma, but data across Europe are lacking.
As part of a multicentric case–control study organised by the Global Allergy and Asthma
European Network (GA2LEN), it was examined whether or not frequent paracetamol use is
associated with adult asthma across Europe. The network compared 521 cases with a diagnosis
of asthma and reporting of asthma symptoms within the last 12 months with 507 controls with no
diagnosis of asthma and no asthmatic symptoms within the last 12 months across 12 European
centres. All cases and controls were selected from the same population, defined by age (20–
45 yrs) and place of residence.
In a random effects meta-analysis, weekly use of paracetamol, compared with less frequent use,
was strongly positively associated with asthma after controlling for confounders. There was no
evidence for heterogeneity across centres. No association was seen between use of other
analgesics and asthma.
These data add to the increasing and consistent epidemiological evidence implicating frequent
paracetamol use in asthma in diverse populations.
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S
ince the year 2000, evidence has been
accumulating that frequent paracetamol
(acetaminophen) use is associated with
asthma in adults. Following the initial finding in
a population-based case–control study of adult
asthma in London (UK) [1], other studies have
replicated these observations. The Nurses Health
Study, in the USA, reported a positive prospec-
tive association between paracetamol use and
incident asthma in females [2]. Positive cross-
sectional associations have also been found in
Ethiopia in relation to allergic symptoms [3], and
in the US National Health and Nutrition
Examination Survey in relation to asthma and
COPD [4]. Positive geographical correlations
between paracetamol sales and asthma, wheeze,
rhinitis and bronchial hyperresponsiveness have
also been observed in adults across Europe [5],
but, given the limitations of ecological studies,
the aim of the present study was to determine
whether or not an association between frequent
paracetamol use and adult asthma could be
confirmed in individuals living in different
environments. As part of a multicentric case–
control study organised by the Global Allergy
and Asthma European Network (GA2LEN),
which was set up primarily to assess the relation
of plasma selenium to adult asthma, the relation
between analgesic use and asthma was examined
in European adults.
METHODS
The present study was a case–control study. The
cases were aged 20–45 yrs, lived in a defined area
and had both a self-reported diagnosis of asthma
and a history of either wheezing, shortness of
breath or waking at night with breathlessness
within the previous 12 months [6]. The controls
lived in the same area, were aged 20–45 yrs and
had neither a diagnosis of asthma nor any of the
three symptoms. In the first instance, cases and
controls were identified from a population-based
survey, mostly through a simple screening ques-
tionnaire sent by post. However, these surveys
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were not always large enough to locate adequate numbers of
cases, and further cases could be recruited from clinics
providing that they met the above criteria and were not being
treated in the clinic for another atopic condition. Each centre
was asked to recruit 50 cases and 50 controls.
Once identified, the participants were invited to complete a
longer administered questionnaire and had their height and
weight measured. Skin tests were undertaken using ALK
(Madrid, Spain) and ALK-Abello´ (Hørsholm, Denmark)
reagents directed against timothy grass, cat dander,
Dermatophagoides farinae, olive, birch, Parietaria, Alternaria
and histamine (10 mg?mL-1) and diluent controls. Atopy was
defined by the very sensitive criterion of any atopic weal of
greater diameter than that of the diluent control in the presence
of a positive histamine control. Asthma cases who showed
night-time symptoms twice or less per month, trouble breath-
ing less than once a day, a forced expiratory volume in one
second of o80% of the predicted value and were using at most
a medium dose of inhaled steroid were classified as having
intermittent and mild persistent disease; those with more
severe symptoms, worse lung function and using higher doses
of steroids were classified as having moderate or severe
persistent disease.
Central training was given to the staff in each centre prior to
involvement with the main data collection. Questionnaires
were forward- and back-translated, and the original ques-
tionnaires and the back-translations compared and reconciled.
Participants were asked how often they took paracetamol and
how often they took other painkillers not containing para-
cetamol (such as aspirin or ibuprofen). The options were:
,1 day?week-1, 1–2 days?week-1, 3–4 days?week-1, 5–6 days?
week-1 and daily. However, since very frequent use turned
out to be uncommon, the top four categories were collapsed
down into one category of weekly for the main analyses.
Socioeconomic status was assessed from the current or last
occupation and classified as professional, managerial, skilled,
semi-skilled, unskilled or student. Smoking status was classified
as: never-smoker exposed to environmental tobacco smoke for
,1 h?day-1; never-smoker exposed to environmental tobacco
smoke for o1 h?day-1; ex-smokers; and current smokers.
Participants were asked whether or not they took regular
vitamin or mineral supplements. After examining the distribu-
tions of the variables, logistic regression was used to estimate
the risk of being a case in each centre. These analyses controlled
for the potential confounders sex, age, smoking, socioeconomic
status, supplement use and body mass index (in kilograms per
metre squared). After initial within-centre analyses, the results
were combined across centres using random effects meta-
analysis.
Local ethical committee approval was obtained in each centre
and approval was given by the Norwegian Data Inspectorate
(Oslo, Norway). Each participant was provided with an
information sheet explaining the study, and signed a consent
form prior to taking part.
RESULTS
The 12 centres recruited a total of 521 cases and 507 controls.
Clinic visits occurred between May 2005 and May 2007.
Table 1 shows the distribution of potential confounders in
cases and controls. Cases were more likely than controls to be
overweight or obese and female, and less likely to be working
in professional jobs. Smoking history, supplement use and
mean age were similar in the two groups. The prevalence of
atopy in cases and controls was 82 and 36%, respectively.
Amongst cases, 54% were classified as having intermittent or
mild persistent disease and the remainder as having moderate
or severe persistent disease.
Table 2 shows the frequency of use of paracetamol and other
analgesics by centre and case–control status. In Italy (Palermo
and Rome), no participants reported weekly paracetamol use,
and the highest frequency of weekly use occurred in
Amsterdam (the Netherlands). Overall, 8.9% of individuals
reported taking paracetamol at least once a week. This was
more common in cases (13.2%) than in controls (4.5%). In the
main paracetamol analyses, three centres were dropped
(Vienna (Austria), Rome and Palermo) as too few individuals
were taking paracetamol weekly and this led to a failure of the
regression model to converge. Similarly, Amsterdam and
Barcelona (Spain) had to be omitted from the analyses of other
analgesic use for the same reason.
Table 3 shows the unadjusted and adjusted odds ratios (ORs)
for asthma according to paracetamol use in each centre, and in
all centres combined. This shows that weekly paracetamol use
(compared with less frequent use) was positively associated
with asthma, and the overall effect estimate became stronger
after controlling for confounders (adjusted OR 2.87; 95%
TABLE 1 Distribution of potential confounders in cases
and controls
Controls Cases Total
Total 507 (49.3) 521 (50.7) 1028
Body mass index
,20 kg?m-2 51 (10.1) 52 (10.0) 103 (10.0)
20–25 kg?m-2 270 (53.3) 238 (45.7) 508 (49.4)
25–30 kg?m-2 135 (26.6) 156 (29.9) 291 (28.3)
o30 kg?m-2 51 (10.1) 73 (14.0) 124 (12.1)
Male sex 239 (47.1) 206 (39.5) 445 (43.3)
Age yrs 34.7¡7.48 32.8¡7.37 33.7¡7.48
Socioeconomic status
Professional 242 (47.7) 186 (35.7) 428 (41.6)
Managerial 29 (5.7) 28 (5.4) 57 (5.5)
Skilled 139 (27.4) 186 (35.7) 325 (31.6)
Semi-skilled 29 (5.7) 29 (5.6) 58 (5.6)
Unskilled 27 (5.3) 39 (7.5) 66 (6.4)
Students 38 (7.5) 43 (8.3) 81 (7.9)
Smoking
Never-smoker 139 (27.4) 142 (27.3) 281 (27.3)
Exposed to environmental
tobacco smoke
142 (28.0) 150 (28.8) 292 (28.4)
Ex-smoker 93 (18.3) 93 (17.9) 186 (18.1)
Current smoker 133 (26.2) 136 (26.1) 269 (26.2)
Supplement use 106 (20.9) 123 (23.6) 229 (22.3)
Data are presented as n (%) n, or mean¡SD.
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confidence interval (CI) 1.49–5.37; p50.002). There was no
significant heterogeneity between centres (p50.61). The meta-
analysis of the adjusted effects is summarised in figure 1.
Table 4 shows the unadjusted and adjusted ORs for asthma
according to other analgesic use in each centre, and in all
centres combined. The overall adjusted effect estimate showed
a nonsignificant positive association with asthma, and, again,
there was no significant heterogeneity between centres. The
meta-analysis of the adjusted effects is summarised in figure 2.
When paracetamol and other analgesic use were included
together in the regression model, the overall adjusted effect
estimate for paracetamol was only slightly attenuated (OR 2.66;
95% CI 1.33–5.33; p50.006). Of the cases, 75% reported rhinitis.
If rhinitis was included in the model, the adjusted OR was
reduced a little to 2.39 (95% CI 1.06–5.37; p50.036).
DISCUSSION
In the present multicentric study across Europe, a positive
association between frequent use of paracetamol and adult
asthma has been confirmed, in keeping with previous studies
of individuals from the UK [1] and USA [2, 4], and ecological
observations across Europe [5]. Weekly users of paracetamol
were more likely than those taking the drug less often to
exhibit asthma, and there was no significant heterogeneity in
this result between centres. No significant relation was seen
between use of other analgesics and asthma.
TABLE 2 Frequency of paracetamol and other analgesic use by centre and case–control status
Paracetamol Other analgesics
,1# 1–2# o3# Total ,1# 1–2# o3# Total
Ghent 125 (91) 10 (7) 3 (2) 138 128 (93) 8 (6) 2 (1) 138
Vienna 58 (98) 1 (2) 0 (0) 59 54 (92) 8 (8) 0 (0) 59
Odense 78 (86) 7 (8) 6 (7) 91 83 (91) 4 (4) 4 (4) 91
Berlin 60 (95) 2 (3) 1 (2) 63 59 (94) 0 (0) 4 (6) 63
Palermo 94 (100) 0 (0) 0 (0) 94 83 (88) 11 (12) 0 (0) 94
Rome 49 (100) 0 (0) 0 (0) 49 43 (88) 2 (4) 4 (8) 49
Amsterdam 63 (78) 16 (20) 2 (2) 81 80 (99) 1 (1) 0 (0) 81
Ło´dz´ 92 (96) 2 (2) 2 (2) 96 91 (95) 3 (3) 2 (2) 96
Coimbra 87 (86) 8 (8) 6 (6) 101 93 (92) 4 (4) 4 (4) 101
Barcelona 87 (89) 8 (8) 3 (3) 98 95 (97) 1 (1) 2 (2) 98
Stockholm 50 (91) 4 (7) 1 (2) 55 49 (89) 4 (7) 2 (2) 55
London 93 (90) 7 (7) 3 (3) 103 95 (92) 3 (3) 5 (5) 103
Cases 452 (86.8) 49 (9.4) 20 (3.8) 521 473 (90.8) 28 (5.4) 20 (3.8) 521
Controls 484 (95.5) 16 (3.1) 7 (1.4) 507 480 (94.7) 18 (3.6) 9 (1.8) 507
Total 936 (91.1) 65 (6.3) 27 (2.6) 1028 953 (92.7) 46 (4.5) 29 (2.8) 1028
Data are presented as n (%) or n. #: days?week-1.
TABLE 3 Association of asthma with frequency of paracetamol use
,1 day?week-1 OR o1 day?week-1
Unadjusted OR (95% CI) p-value Adjusted# OR (95% CI) p-value
Ghent 1.00 4.61 (0.98–21.66) 0.05 5.20 (0.97–27.77) 0.05
Odense 1.00 1.93 (0.55–6.79) 0.31 2.88 (0.53–15.58) 0.22
Berlin 1.00 3.00 (0.26–34.95) 0.38 1.86 (0.07–47.03) 0.71
Amsterdam 1.00 1.38 (0.48–3.94) 0.55 1.17 (0.32–4.26) 0.82
Ło´dz´ 1.00 2.63 (0.26–26.26) 0.41 4.30 (0.16–117.32) 0.39
Coimbra 1.00 14.59 (1.83–116.39) 0.01 16.11 (1.25–207.41) 0.03
Barcelona 1.00 12.89 (1.58–105.18) 0.02 14.34 (1.25–164.53) 0.03
Stockholm 1.00 1.88 (0.19–18.23) 0.59 2.77 (0.11–68.54) 0.53
London 1.00 1.67 (0.44–6.31) 0.45 1.73 (0.36–8.34) 0.49
Overall 1.00 2.57 (1.51–4.37) 0.001 2.87 (1.49–5.37) 0.002
In testing for heterogeneity (Cochran’s Q) of the combined results that contributed towards the overall mean result, Chi-squared57.55 (8 degrees of freedom (df);
p50.48) for unadjusted values and 6.29 (8 df; p50.61) for adjusted values. OR: odds ratio; CI: confidence interval. #: adjusted for age, sex, body mass index,
socioeconomic status, smoking and supplement use.
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A strength of the present study is that the methods and
definitions used were standardised across centres. However,
it had some limitations. First, most individuals took para-
cetamol ,1 day?week-1, and the questions on analgesic use
permitted neither the categorisation of infrequent use in more
detail nor distinction of those who never took paracetamol.
Furthermore, there were insufficient numbers of weekly users
to permit the further breakdown of this category. Hence it was
not possible to determine whether or not a dose–response
relation was present. Secondly, the cross-sectional nature
of the association makes a causal interpretation difficult,
although taking paracetamol for asthma symptoms (reverse
causation) seems unlikely, and findings from a cohort study
in the USA have indicated that frequent paracetamol use
preceded the development of adult-onset asthma [2]. Thirdly,
separate questions about frequency of use of aspirin and
nonsteroidal anti-inflammatory drugs were not asked,
although these are likely to have been the most commonly
used non-paracetamol-containing analgesics. Were the expla-
nation of the paracetamol findings avoidance of aspirin and
nonsteroidal anti-inflammatory drugs by asthmatic indivi-
duals, a negative association between other analgesic use and
asthma would have been expected, which was not the case.
Finally, in an observational study of this kind, the possibility
that the association between paracetamol use and asthma has
arisen through bias or unmeasured or residual confounding
cannot be ruled out. However, cases and controls were selected
from similar populations in each centre, making selection bias
less likely. Information was not collected on indications for
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FIGURE 1. Forest plot showing meta-analysis of asthma risk according to
weekly paracetamol use (versus less than weekly use). Data are presented as
adjusted odds ratios (ORs; & (size reflects weighting)), using a random effect
model, and 95% confidence intervals (horizontal bars). The centre of the diamond
indicates the combined mean effect of the studies (OR 2.87; - - - - - -) and its
extremities, the 95% confidence interval (..........: line of no effect).
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FIGURE 2. Forest plot showing meta-analysis of asthma risk according to
weekly use of painkillers other than paracetamol (versus less than weekly use). Data
are presented as adjusted odds ratios (ORs; & (size reflects weighting)), using a
random effect model, and 95% confidence intervals (horizontal bars). The centre of
the diamond indicates the combined mean effect of the studies (OR 1.85; - - - - - -)
and its extremities, the 95% confidence interval (..........: line of no effect).
TABLE 4 Association of asthma with other painkiller use
,1 day?week-1 OR o1 day?week-1
Unadjusted OR (95% CI) p-value Adjusted# OR (95% CI) p-value
Ghent 1.00 1.13 (0.30–4.20) 0.86 1.94 (0.37–10.34) 0.44
Vienna 1.00 0.88 (0.09–8.58) 0.91 0.14 (0.001–14.86) 0.41
Odense 1.00 2.53 (0.48–13.29) 0.27 3.80 (0.35–41.49) 0.27
Berlin 1.00 4.70 (0.46–47.92) 0.19 8.02 (0.39–165.49) 0.18
Palermo 1.00 1.04 (0.29–3.66) 0.96 0.26 (0.02–2.96) 0.28
Rome 1.00 4.35 (0.47–40.39) 0.20 9.97 (0.69–143.64) 0.09
Ło´dz´ 1.00 3.58 (0.39–33.31) 0.26 8.63 (0.41–183.41) 0.17
Coimbra 1.00 1.50 (0.34–6.63) 0.60 1.04 (0.18–6.05) 0.97
Stockholm 1.00 2.42 (0.26–22.51) 0.44 22.11 (0.57–855.75) 0.10
London 1.00 1.07 (0.25–4.51) 0.93 0.62 (0.11–3.47) 0.58
Overall 1.00 1.60 (0.94–2.73) 0.09 1.85 (0.79–4.31) 0.15
In testing for heterogeneity (Cochran’s Q) of the combined results that contributed towards the overall mean result, Chi-squared53.84 (9 degrees of freedom (df);
p50.92) for unadjusted values and 11.13 (9 df; p50.27) for adjusted values. OR: odds ratio; CI: confidence interval. #: adjusted for age, sex, body mass index,
socioeconomic status, smoking and supplement use.
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use, however, and, although it is possible that a minority of
cases were taking paracetamol for conditions that are more
common in people with asthma, such as rhinitis or migraine, it
seems unlikely that such confounding would be of sufficient
magnitude to account for the effect estimate for frequent
paracetamol use. A previous case–control study indicated that
the majority of adults with asthma take weekly paracetamol for
non-migrainous headache and musculoskeletal complaints, and
only a minority take it for migraine or rhinitis, at least in the UK
[1]. Furthermore, when rhinitis was controlled for in the present
study, the overall effect estimate was only attenuated a little,
indicating minor confounding, but suggesting that use of
paracetamol for rhinitis is unlikely to be the major explanation
for the association between paracetamol use and asthma.
It has previously been suggested that glutathione depletion in the
airways and increased oxidative stress may be the mechanism
underlying the link between frequent paracetamol use and
asthma [1]. Although evidence is lacking regarding the effects of
therapeutic doses of paracetamol on airway glutathione levels, in
vitro studies have shown that clinically relevant doses of
paracetamol can deplete intracellular reduced glutathione levels
in animal alveolar macrophages and type 2 pneumocytes [7] and
human pulmonary macrophages in vitro [8], and that depletion of
glutathione in antigen-presenting cells leads to preferential type-2
T-helper cell responses [9]. Furthermore, an in vivo study in
humans demonstrated reductions in the antioxidant capacity of
the blood following maximum therapeutic doses of paracetamol
for 2 weeks [10], although reduced glutathione levels were not
measured. The present authors, therefore, believe that frequent
therapeutic doses of paracetamol may, in susceptible individuals,
have adverse effects on the lung, through either oxidative
damage to the airways or promotion of atopic responses, with
consequences for asthma.
Given the increasing and consistent epidemiological evidence
implicating paracetamol in adult asthma across diverse
populations, and the high prevalence of asthma and para-
cetamol use in some countries, there is now a need to carry out
suitable intervention studies in order to determine whether or
not the link is causal.
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